Rifaximin-α (Targaxan®550mg)
Last Updated: 25th March, 2015

The Effective Shared Care Agreement Toolkit (rifaximin-α [Targaxan®550mg]) was last updated on the 25th March 2015.  As a result, the content reflects the approved prescribing information (SPC) for rifaximin-α at that time and it has not been updated in the intervening period.  You can still access the rifaximin-α ESCA Toolkit but you should do so in the full knowledge that the content may not be fully up-to-date.

Successful shared care arrangements enable the combination of the best of both primary and secondary care for the benefit of the patient. They allow the seamless transfer of patient treatment from the secondary care sector to general practice. While protocols and guidelines may be useful, they in themselves do not constitute an adequate basis for shared care operations.

This Effective Shared Care Agreement Toolkit (rifaximin-α [Targaxan®550mg]) is designed to assist healthcare professionals in the development of their own shared care agreements to support locally agreed policy on the prescribing of rifaximin-α for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age. In particular, it suggests ways in which responsibilities can be shared between the secondary care specialist and general practitioner (GP) / primary care prescriber. The Toolkit is intended to act as a flexible template that enables users to consider suggested content and tailor it to local circumstances and requirements.

Please note that the Effective Shared Care Agreement Toolkit is not a recommendation to prescribe rifaximin-α. The decision to prescribe rifaximin-α is the responsibility of the respective local healthcare organisation and the Toolkit should only be used after the local decision to prescribe rifaximin-α has been taken.

To support your local decision-making you may wish to refer to:

Further support materials are available from the manufacturer - patient medication record, patient compliance aid and trail making test.  If you would like copies of any of the manufacturer's support materials, please contact Norgine Pharmaceuticals medical information on 01895 826606 or email medinfo@norgine.com.

The Effective Shared Care Agreement Toolkit and Keele University's work in developing shared care resources has been recognised by the General Medical Council in their guidance 'Good practice in prescribing and managing medicines and devices' (January 2013).

Keele University is not responsible for the content of any linked site or manufacturer's material. Listing and linking should not be taken as an endorsement of any kind and we accept no liability in respect of the content.

Enter the
ESCA Toolkit

Agreement Library

ESCA Title Organisation Author Date Added  
Rifaximin ESCA MTRAC MTRAC 10/03/14

Upload an existing agreement to the library here.


Supported by an educational grant provided by Norgine Pharmaceuticals Limited in the UK. Norgine Pharmaceuticals had no editorial involvement but reviewed content for technical accuracy.